{
  "functional_evidence_assessment": {
    "variant_id": {
      "Gene": "LRRK2",
      "Protein_Change": {
        "ref": "Y1699",
        "alt": "C",
        "position": "1699"
      },
      "variant_string_id": "LRRK2 Y1699C"
    },
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The study explored the effects of the Y1699C mutation on GTPase activity and interactions within the catalytic core of LRRK2.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly describes the functional impact of the Y1699C variant on LRRK2's GTPase activity and its role in the disease mechanism."
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The study used a competition assay to demonstrate intra-molecular ROC:COR interaction strength.",
        "judgment": "Yes",
        "reasoning": "The use of a competition assay is applicable to assess the functional impact of the mutation on protein interactions, which aligns with the disease mechanism."
      },
      {
        "step_name": "Step 3: Evaluate validity of specific instances of assays",
        "extracted_paper_info": "The study used variant controls known pathogenic variants to validate their findings.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly states that known pathogenic variants were used as controls, supporting the assay's validity."
      },
      {
        "step_name": "Step 4: Apply evidence to individual variant interpretation",
        "extracted_paper_info": "Statistical analyses in the study suggest a decrease in GTPase activity comparable to other mutations.",
        "judgment": "No",
        "reasoning": "While statistical analyses are mentioned, specific OddsPath values or detailed counts of controls are not provided."
      },
      {
        "step_name": "Sub-step 4b: No OddsPath Calculation",
        "extracted_paper_info": "The study does not provide direct OddsPath calculations but mentions the use of known pathogenic variants as controls.",
        "judgment": "No",
        "reasoning": "Without specific statistical data, it's challenging to apply standard thresholds for PS3 or BS3."
      },
      {
        "step_name": "Sub-step 4c: Correlate OddsPath",
        "extracted_paper_info": "The study does not provide direct OddsPath values but infers pathogenicity from observed effects.",
        "judgment": "No",
        "reasoning": "Without explicit OddsPath data, it's difficult to assign a supporting strength."
      }
    ],
    "final_evidence_strength": "PS3_supporting",
    "internal_commentary": "The paper provides evidence that the Y1699C mutation affects LRRK2's GTPase activity, a key function likely involved in disease pathology. The use of variant controls strengthens this interpretation, though without specific statistical measures or OddsPath values, it is challenging to assign a definitive strength level beyond supporting."
  }
}